| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab67ba05dcbedf0fed52674694108ca8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3c6f6ab0b69584e0bba483b29398a7a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30170e37bade06fb331b7fa2f83c72ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1956c6848add0573bc477a00f0f05b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_232ab9c0497281d806d9a53303d4a4a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4461512c3d9a75303d3feb25e8cf7bbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6eb0602346e3fd8259cde5f61e5c049 |
| publicationDate |
2013-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2013121072-A1 |
| titleOfInvention |
Inhibitor of the production of soluble endoglin and use thereof in pathological conditions in which soluble endoglin has a pathogenic effect |
| abstract |
The invention relates to an isolated peptide derived from endoglin, characterised in that the amino acid sequence thereof comprises a cleavage site GL for extracellular matrix metalloproteinase 14 (MMP-14 or MT1- MMP), and in that it can block the proteolytic cleavage of the endoglin using MMP-14. The invention also relates to a pharmaceutical composition characterised in that it comprises, by way of active ingredient, at least one endoglin-derived peptide as defined above. The invention further relates to the use of at least one of said endoglin-derived peptides or a pharmaceutical composition as defined above for the treatment of a disorder or disease associated with soluble endoglin (sEng) or with MMP-14. |
| priorityDate |
2012-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |